TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Dermata Therapeutics ( (DRMA) ) is now available.
Dermata Therapeutics announced a strategic shift from prescription dermatology products to over-the-counter (OTC) skincare solutions, with plans to launch a once-weekly acne kit in mid-2026. This pivot aims to leverage Dermata’s scientific expertise and innovative Spongilla technology to meet consumer demand for accessible skincare, potentially enhancing the company’s market position and value for stakeholders.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatologic solutions, focusing on the development and distribution of over-the-counter (OTC) pharmaceutical skin treatments. The company is headquartered in San Diego, California, and is currently developing a once-weekly acne kit utilizing its Spongilla technology, with plans to launch in mid-2026.
Average Trading Volume: 136,914
Technical Sentiment Signal: Sell
Current Market Cap: $2.13M
For detailed information about DRMA stock, go to TipRanks’ Stock Analysis page.